

Cosetta Ravelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4097660/publications.pdf>

Version: 2024-02-01

34
papers

767
citations

566801

15
h-index

525886

27
g-index

34
all docs

34
docs citations

34
times ranked

1175
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166313.	1.8	2
2	Production and Biochemical Characterization of Dimeric Recombinant Gremlin-1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1151.	1.8	3
3	Irisin regulates thermogenesis and lipolysis in 3T3-L1 adipocytes. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022, 1866, 130085.	1.1	19
4	A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. <i>Cancer Letters</i> , 2021, 496, 84-92.	3.2	7
5	Simultaneously characterization of tumoral angiogenesis and vasculogenesis in stem cell-derived teratomas. <i>Experimental Cell Research</i> , 2021, 400, 112490.	1.2	2
6	Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells. <i>Cancers</i> , 2021, 13, 2255.	1.7	6
7	Inactive VEGFR2(R1032Q) exerts pro-oncogenic activity through heterodimerization with wild-type receptor. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
8	Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. <i>Cancer Letters</i> , 2021, 507, 80-88.	3.2	8
9	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. <i>Blood</i> , 2021, 138, 1705-1720.	0.6	10
10	Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188614.	3.3	2
11	The Metastatic Capacity of Melanoma Reveals Alternative Pathways of Cancer Dissemination. <i>International Journal of Translational Medicine</i> , 2021, 1, 163-174.	0.1	1
12	Glyco-Coated CdSe/ZnS Quantum Dots as Nanoprobes for Carbonic Anhydrase IX Imaging in Cancer Cells. <i>ACS Applied Nano Materials</i> , 2021, 4, 14153-14160.	2.4	11
13	Î²-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 251.	1.8	5
14	Molecular insight on the altered membrane trafficking of TrkA kinase dead mutants. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118614.	1.9	15
15	In Situ DNA/Protein Interaction Assay to Visualize Transcriptional Factor Activation. <i>Methods and Protocols</i> , 2020, 3, 80.	0.9	3
16	Fluorolabeling of the PPTase-Related Chemical Tags: Comparative Study of Different Membrane Receptors and Different Fluorophores in the Labeling Reactions. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 195.	1.6	10
17	A Model of Integrin and VEGF Receptors Recruitment on Endothelial Cells. <i>Advanced Structured Materials</i> , 2020, , 163-198.	0.3	2
18	VEGFR2 activation mediates the pro-angiogenic activity of BMP4. <i>Angiogenesis</i> , 2019, 22, 521-533.	3.7	33

#	ARTICLE	IF	CITATIONS
19	Natural Hydrogel-Based Bio-Scaffolds for Sustaining Angiogenesis in Beige Adipose Tissue. <i>Cells</i> , 2019, 8, 1457.	1.8	10
20	Claudin3 is localized outside the tight junctions in human carcinomas. <i>Oncotarget</i> , 2018, 9, 18446-18453.	0.8	15
21	3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. <i>Angiogenesis</i> , 2017, 20, 629-640.	3.7	16
22	Multi-physics interactions drive VEGFR2 relocation on endothelial cells. <i>Scientific Reports</i> , 2017, 7, 16700.	1.6	19
23	Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. <i>Oncotarget</i> , 2016, 7, 35353-35368.	0.8	34
24	Vascular disrupting activity of combretastatin analogues. <i>Vascular Pharmacology</i> , 2016, 83, 78-89.	1.0	17
25	β_3 Integrin Promotes Long-Lasting Activation and Polarization of Vascular Endothelial Growth Factor Receptor 2 by Immobilized Ligand. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2161-2171.	1.1	16
26	Cyclic Adenosine Monophosphate-Response Element-Binding Protein Mediates the Proangiogenic or Proinflammatory Activity of Gremlin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 136-145.	1.1	45
27	Involvement of β_3 integrin in gremlin-induced angiogenesis. <i>Angiogenesis</i> , 2013, 16, 235-243.	3.7	42
28	Long Pentraxin-3 Inhibits Epithelial-Mesenchymal Transition in Melanoma Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2760-2771.	1.9	68
29	Substrate-Immobilized HIV-1 Tat Drives VEGFR2/ β_3 Integrin Complex Formation and Polarization in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, e25-34.	1.1	15
30	Role of Nanomechanics in Canonical and Noncanonical Pro-angiogenic Ligand/VEGF Receptor-2 Activation. <i>Journal of the American Chemical Society</i> , 2012, 134, 14573-14579.	6.6	24
31	Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, e116-27.	1.1	62
32	Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. <i>Blood</i> , 2010, 116, 3677-3680.	0.6	163
33	Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Dm. <i>Blood</i> , 2008, 112, 1154-1157.	0.6	37
34	Heparin-Mimicking Sulfonic Acid Polymers as Multitarget Inhibitors of Human Immunodeficiency Virus Type 1 Tat and gp120 Proteins. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2337-2345.	1.4	45